BridgeBio JPM Presentation_January 2025.pdf

1、J.P.Morgan PresentationJanuary 13,20252Forward Looking Statements and DisclaimerThe presentation contains forward-looking statements.Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securitie

2、s Act of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,as amended.Words such as“believe,”“anticipate,”“plan,”“expect,”“intend,”“will,”“may,”“goal,”“potential,”“should,”“could,”“aim,”“estimate,”“predict,”“continue”and similar expressions or the negative of these terms or othe

3、r comparable terminology are intended to identify forward-looking statements,though not all forward-looking statements necessarily contain these identifying words.We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Sectio

4、n 27A of the Securities Act and Section 21E of the Exchange Act.These forward-looking statements,including express and implied statements relating to the commercial success of Attruby,the timing of ongoing clinical trials,including BridgeBio Oncology Therapeutics and Gondola Bios clinical trials,the

5、 clinical,therapeutic and market potential of our clinical development programs and our pipeline,BridgeBio Oncology Therapeutics pipeline and Gondola Bios pipeline,our speed of creating new and meaningful drugs and related impact on patients,the efficiency of our engine to rapidly and efficiently de

6、liver medicines,our value creation potential for patients,the potential market sizes and opportunities,the safety,efficacy and mechanisms of our newly FDA-approved Attruby(acoramidis)and other later-stage products including infigratinib,BBP-418 and encaleret,the timing of approval of Attruby for ATT